Equities
Health CarePharmaceuticals and Biotechnology
  • Price (USD)137.11
  • Today's Change5.43 / 4.12%
  • Shares traded2.03m
  • 1 Year change+47.01%
  • Beta1.1103
Data delayed at least 15 minutes, as of Nov 21 2024 20:59 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Illumina, Inc. is engaged in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Its products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. Its product categories include Instruments, Kits & Reagents, Selection Tools, and Software & Analysis. Its Instruments category include sequencing platforms, microarray scanners, and IVD instruments. Its Kits & Reagents category consists of library preparation kits, sequencing reagents, microarray kits, clinical research products, and IVD products. Its Selection Tools category include Library Prep & Array Kit Selector, Gene Panel & Array Finder, DesignStudio Custom Assay Designer, and other. Its services include sequencing services, microarray services, proactive instrument monitoring, and instrument services and training. It is also a developer of an emerging and highly differentiated single-cell technology.

  • Revenue in USD (TTM)4.39bn
  • Net income in USD-1.58bn
  • Incorporated2000
  • Employees10.59k
  • Location
    Illumina Inc5200 Illumina WaySAN DIEGO 92122-4616United StatesUSA
  • Phone+1 (858) 202-4500
  • Fax+1 (858) 202-4766
  • Websitehttps://www.illumina.com
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Globus Medical Inc2.48bn91.51m13.47bn5.00k127.952.8438.505.430.66360.663618.0829.940.47471.284.58495,719.201.756.901.997.4558.1471.733.6914.051.64--0.09740.0053.3417.08-35.39-4.725.57--
Revvity Inc2.72bn258.26m13.52bn11.50k53.041.7119.694.972.092.0622.0664.880.20782.894.37236,657.001.974.762.155.3955.4457.199.4915.342.9711.960.28696.52-16.95-0.1982-64.99-5.28-2.690.00
Avantor Inc6.82bn309.60m13.86bn14.50k44.812.5019.392.030.45440.454410.018.160.5325.566.09470,331.002.422.972.753.3533.5333.444.545.061.063.290.46980.00-7.263.51-51.52--31.17--
Baxter International Inc11.77bn225.00m16.83bn60.00k74.632.1412.841.430.4420.21423.1015.420.41052.915.42196,133.300.81980.19421.050.233338.4338.202.000.36741.093.810.61961,398.942.125.9497.15--0.9829.71
Align Technology, Inc.3.96bn441.57m17.04bn21.61k38.904.3329.264.305.875.8752.6352.760.62454.324.14183,272.506.9616.3410.3924.1469.9871.7211.1523.161.14--0.000.003.4214.4523.092.15-4.46--
Hologic Inc4.03bn789.50m18.28bn6.99k23.713.5616.644.543.323.3216.9722.090.44062.726.57--8.6313.129.8415.2056.2560.8219.5924.753.0364.450.3307---0.00253.6673.14--4.30--
Insulet Corp1.98bn420.90m18.38bn3.00k45.5516.4436.839.265.755.7525.9615.940.72231.426.14661,300.0015.322.7118.563.1469.3665.8121.224.282.8098.710.55570.0030.0224.664,384.78128.77-7.63--
Cooper Companies Inc3.80bn359.30m19.90bn15.00k55.642.5127.035.231.801.8019.0239.800.31961.705.56253,606.703.0210.063.2911.3466.3665.549.4529.001.185.460.24930.34698.617.24-23.74-3.6615.180.00
Steris PLC5.12bn602.62m21.30bn18.18k35.513.2319.234.166.084.3851.6266.800.47583.865.49281,655.405.625.196.105.6843.0143.6411.8110.971.558.290.252836.5613.2813.06-1.0712.6713.698.83
Zimmer Biomet Holdings Inc7.60bn1.08bn21.58bn18.00k20.651.7510.482.845.255.2536.8762.000.35380.91365.38421,972.205.052.215.822.5271.7871.2514.287.280.69877.520.342538.906.55-1.40252.86--9.440.00
Illumina Inc4.39bn-1.58bn21.73bn10.59k--10.25--4.95-10.00-10.0027.6113.360.54412.666.17414,542.00-19.63-6.20-23.16-7.2863.9466.39-36.08-15.481.8538.440.4834---1.756.2173.64---7.91--
Waters Corp2.91bn622.64m21.88bn7.90k35.1613.6526.867.5310.4810.4848.8927.000.6452.204.47367,740.1013.8219.7716.7225.2959.7358.4521.4323.381.3810.110.53250.00-0.52294.09-9.261.534.72--
West Pharmaceutical Services Inc.2.88bn499.60m23.24bn10.60k47.558.4536.648.086.756.7538.8637.960.77434.505.51271,358.5013.0215.6115.1618.6534.8738.0616.8118.472.23--0.069510.692.1811.432.2823.7628.166.20
DexCom Inc3.95bn680.80m29.08bn9.60k45.4514.7032.567.361.641.649.525.070.61072.764.42411,875.0010.518.3014.2810.5062.1065.9017.2214.142.12--0.55790.0024.4928.5658.70--28.66--
Data as of Nov 21 2024. Currency figures normalised to Illumina Inc's reporting currency: US Dollar USD

Institutional shareholders

36.19%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 30 Sep 202415.53m9.75%
BlackRock Fund Advisorsas of 30 Sep 202413.76m8.64%
SSgA Funds Management, Inc.as of 30 Sep 20245.61m3.52%
Loomis, Sayles & Co. LPas of 30 Sep 20244.34m2.73%
Baillie Gifford & Co.as of 30 Sep 20243.62m2.27%
Capital Research & Management Co. (World Investors)as of 30 Sep 20243.54m2.23%
WCM Investment Management LLCas of 30 Sep 20243.26m2.05%
Geode Capital Management LLCas of 30 Sep 20242.73m1.71%
GuardCap Asset Management Ltd.as of 30 Sep 20242.72m1.71%
PRIMECAP Management Co.as of 30 Sep 20242.52m1.58%
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.